A CBD cream applied to the skin reduced paralysis and brain inflammation in mice with MS-like disease | Research

The takeaway

Daily topical application of 1% CBD cream reduced disease severity from a mean score of 5.0 to 1.5, recovered hind limb paralysis, and decreased brain inflammation in a mouse MS model.

Read this if you have MS and are curious about whether topical CBD might help.

Disease score dropped from 5.0 to 1.5 with topical CBD cream

What the researchers found

Researchers tested a topical 1% CBD cream formulation in mice with experimental autoimmune encephalomyelitis (EAE), the standard animal model for multiple sclerosis. When applied daily after disease onset, the CBD cream produced striking results.

Clinical disease scores dropped from a mean of 5.0 in untreated EAE mice to 1.5 in CBD-treated mice. The cream recovered hind limb paralysis and reduced the histological hallmarks of MS: lymphocyte infiltration and demyelination in spinal cord tissue.

At the molecular level, CBD cream reduced inflammatory immune cell markers (CD4 and CD8 T cells in the spleen), pro-inflammatory cytokines, markers of oxidative injury (nitrotyrosine, iNOS), and markers of programmed cell death (cleaved caspase 3). The effects were described as "surprisingly" robust for a topical application.

Why it matters

Topical application is appealing because it avoids many systemic side effects. If CBD cream can reduce neuroinflammation when applied to the skin, it could offer MS patients a simple, well-tolerated add-on treatment to current therapies.

The numbers in context

Clinical score: 5.0 (EAE) vs. 1.5 (EAE + CBD cream). CD4 T cells: ~10.69% positive staining. CD8 T cells: ~35.96% positive staining (both in EAE). Reduced: pro-inflammatory cytokines, p-selectin, GFAP, oxidative markers, apoptosis markers.

How the study worked

Controlled animal study using C57BL/6 mice with MOG-induced EAE. Daily topical 1% CBD cream (CBD dissolved in propylene glycol and basic O/A cream) applied after symptom onset. Multiple experimental groups including naive, EAE, EAE+CBD cream, and vehicle controls. Assessed by daily clinical scoring, histological evaluation, immunohistochemistry, and western blotting at day 28.

What this study cannot tell us

Mouse model of MS does not fully replicate human disease. The mechanism by which topical application reaches the central nervous system is not explained. Single CBD concentration tested. No comparison to oral CBD administration. Results have not been replicated in humans.

How to read the evidence

Controlled animal study with comprehensive molecular analysis. No human data for topical CBD in MS.

When this study was published

Published in 2015. Topical CBD research has expanded but human MS trials remain limited.

The bigger picture

Topical CBD has become a massive consumer market, but scientific evidence for meaningful therapeutic effects through skin application has been limited. This study provides some of the strongest preclinical evidence that topical CBD can produce systemic anti-inflammatory effects, though the mechanism of absorption from skin to brain remains unclear.

Questions still open

How does topical CBD reach the central nervous system to produce these effects? Would human skin absorption be sufficient for therapeutic concentrations? Could this approach complement existing MS treatments?

Common questions

Does CBD cream work for MS?

In this mouse study, daily topical 1% CBD cream dramatically reduced disease severity, recovered paralysis, and decreased brain inflammation. Whether this translates to human MS has not been tested in clinical trials.

How could a skin cream affect the brain?

This is an open question. The study demonstrated clear central nervous system effects from topical application, but the mechanism by which CBD reaches the brain through the skin was not fully explained.

Read the original research

A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 23, 48

View on PubMed ↗Publisher’s paper ↗

Citation

Giacoppo, Sabrina; Galuppo, Maria; Pollastro, Federica; Grassi, Gianpaolo; Bramanti, Placido; Mazzon, Emanuela. (2015). A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 23, 48. https://doi.org/10.1186/s40199-015-0131-8